awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q38379114-261B70E7-3DD7-49D4-814D-E696A9114537
Q38379114-261B70E7-3DD7-49D4-814D-E696A9114537
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38379114-261B70E7-3DD7-49D4-814D-E696A9114537
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors.
P2860
Q38379114-261B70E7-3DD7-49D4-814D-E696A9114537
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38379114-261B70E7-3DD7-49D4-814D-E696A9114537
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
33acca0bd0d6677ed15bc704edde6cbf585f1311
P2860
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.